Phathom Pharmaceuticals, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.01M-4.18M-4.58M-6.79M-27.30M0.68M55.25M
Cost of Revenue 0.17M7.97M
Gross Profit -0.01M-4.18M-4.58M-6.79M-27.30M0.52M47.28M
Operating items
Research & Development 0.02M20.37M98.15M72.34M71.44M49.90M34.08M
Selling, General & Administrative 1.21M6.94M27.52M62.74M101.00M117.93M290.66M
Other Operating Expenses 78.90M
Operating Expenses 1.23M106.22M125.67M135.08M172.44M167.83M324.75M
Operating Income -1.23M-106.22M-125.67M-135.08M-172.44M-167.31M-277.47M
EBIT -1.23M-106.22M-125.67M-135.08M-172.44M-167.31M-277.47M
Non-operating items
Interest & Investment Income 1.09M1.09M0.04M2.13M7.88M15.16M
Other Non Operating Income -0.01M-0.01M-2.06M-0.11M-0.19M-0.01M
Non Operating Income -0.06M-148.92M-3.40M-8.80M-25.28M-34.28M-56.86M
Net income details
EBT -1.24M-109.30M-129.16M-141.83M-197.61M-201.40M-334.32M
Profit After Tax -1.29M-255.13M-129.07M-143.88M-197.72M-201.59M-334.33M
Income from Continuing Operations -1.24M-109.30M-129.16M-141.83M-197.61M-201.40M-334.32M
Consolidated Net Income -1.24M-109.30M-129.16M-141.83M-197.61M-201.40M-334.32M
Income towards Parent Company -1.24M-109.30M-129.16M-141.83M-197.61M-201.40M-334.32M
Net Income towards Common Stockholders -1.24M-109.30M-129.16M-141.83M-197.61M-201.40M-334.32M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 24.53M28.96M31.41M41.62M57.25M68.38M
Shares Outstanding (Diluted Average) 39.12M51.29M63.18M
EBITDA -1.23M-106.22M-125.67M-135.08M-172.44M-167.31M-277.47M